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Abstract 
A series of tetraamine-based compounds was prepared and their trypanocidal effects 
against Trypanosoma cruzi and cytotoxicity were determined through the determination of 
IC50 values. In vivo assays were performed in mice, where parasitaemia levels were 
quantified by fresh blood examination and the assignment of a cure was determined by 
PCR and reactivation of blood parasitaemia levels after immunosuppression. The 
mechanisms of action were elucidated at metabolic and ultra-structural levels, by 1H NMR, 
Fe-SOD inhibition, and TEM studies. The high-selectivity indexes observed in vitro were 
the basis of promoting one of the tested compounds to in vivo assays. Compound 6 induced 
a remarkable decrease in the reactivation of parasitaemia after immunosuppression and 
curative rates of 33%. The experiments allowed us to select Compound 6 as a promising 
candidate for treating Chagas disease, but a further high-level study should be considered 
to obtain an improved efficiency. 
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Introduction 
The World Health Organisation (WHO) lists Chagas disease as one of the most neglected 
tropical diseases. Chagas disease is endemic in Latin America; it is estimated that 10 
million people are infected worldwide and more than 25 million are living at risk of 
infection.1 The main drugs used for the treatment of Chagas disease are benznidazole (Bz, 
LAFEPE) and nifurtimox (Lampit®, Bayer), which present significant side effects and cure 
<20% of patients with chronic Chagas disease.2 Thus, many researchers have combined 
efforts to discover drugs against new targets, looking for lower toxicity and a greater 
tolerance in patients, aiming not only for efficiency in the acute phase, but also in the 
chronic phase.  
One of the self-defence strategies of Trypanosoma cruzi (the etiological agent of Chagas 
disease) is its highly active and exclusive iron superoxide dismutase (Fe-SOD), which 
differs from Cu–Zn-SOD or Mn-SOD operating in mammals. Fe-SOD is an extremely 
efficient enzyme for preventing any oxidative damage from the host in combination with 
peroxidases. So this enzyme is a parasitic molecule involved in protozoan protection 
against oxidative stress, which is now considered a virulence factor of T. cruzi.3  
In previous work, we designed iron and manganese coordination complexes containing 
polyamine ligands, which were capable of generating highly oxidising species.4–6 Highly 
reactive Mn(IV)=O and Fe(IV)=O species embedded in these ligand scaffolds have been 
prepared and their oxidative reactivity studied. Furthermore, these polyamine ligands bind 
very strongly to iron and manganese ions, forming coordination complexes that are stable 
under highly acidic and oxidative conditions.  
Herein, we report on the in vitro and in vivo anti-trypanosomal properties of Mn-based 
polyamines and polyamine complexes (Fig. 1), which represent a class of compounds 
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that have, so far, only rarely been explored for Chagas disease chemotherapy. Finally, 
we analyse the possible mechanism of action over the parasite structure and function as 
well as the protective enzymes mentioned above. 
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Materials and methods 
Chemistry  
Comp 4 was purchased from Catexcel. Compounds 1,7 3,8 5,7 6,9 were prepared as 
described in the literature. 
Synthesis of comp 2: Comp 4 (47.1 mg, 0.14 mmols) was dissolved in acetonitrile (1 mL). 
A solution of FeCl2 (36.2 mg, 0.28 mmols) in acetonitrile (2 mL) was prepared under inert 
atmosphere. The solution of FeCl2 was added dropwise at room temperature to the solution 
of 4, the mixture turned pale yellow and was stirred at room temperature for 1 hour. Then, 
AgClO4 (114.7 mg, 0.55 mmols) was added and the formation of a white precipitate was 
observed. The mixture was stirred over 30 minutes. Afterwards a white powder and a 
purple solution were clearly distinguished. The purple solution was filtered through 
syringe filters (25 mm Ø) and the white precipitate was washed with CH3CN until the 
filtrates become colorless. 121 mg of purple crystals (0.11 mmols, 80 %) were obtained 
after diffusion with ethyl ether. Molecular structure was confirmed by single crystal X- ray 
diffraction. Crystals loose acetonitrile upon drying under vacuum, but color is 
instantaneously recovered upon solution in acetonitrile. ESI/MS (CH3CN): 749.1 [M - 
6CH3CN - ClO4]+, 685.0 [FeII2(ClO4)2(OH)(H2O)(TACN2)]+. 1H-NMR (CD3CN): 110.7, 
103.3, 65.8, 38.4, 36.0, 33.1 ppm. Elemental analysis: Anal Calcd. for 
[(C18H40N6)Fe(CH3CN)3](ClO4)4: C, 29.62 %; N, 12.95 %; H, 5.07%. Found: C, 28.9 %; N, 
12.95 %; H, 5.08 %. 
Biological activity: In vitro assays 
Antiprotozoan properties of the compounds were firstly evaluated in vitro against 
epimastigote, amastigote and trypomastigote forms of T. cruzi, and Vero cells were 
used for the determination of unspecific cytotoxicity, according to the methodology 
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described by us.10 Cytotoxicity: Vero cells (EACC number 84113001), originally 
obtained from monkey kidneys, were grown in RPMI (Gibco) supplemented with 10% 
inactivated fetal bovine serum in a humidified 95% air/5% CO2 atmosphere at 37ºC for 
2 days. The compounds and the reference drug (Bz) were dissolved in DMSO (Panreac, 
Barcelona, Spain) at a concentration of 0.01% (v/v). The compounds were added to the 
culture medium at dosages of 100, 50, 25, 10, l, 0.5, 0.25, and 0.1 µM.  After 72 h of 
treatment, the cell viability was determined by flow cytometry. Thus, 100 µL per well 
of propidium iodide solution (100 mg/mL) was added and incubated for 10 min at 28°C 
in darkness. Afterwards, 100 µL per well of fluorescein diacetate (100 ng/mL) was 
added and incubated under the same conditions. Finally, the cells were recovered by 
centrifugation at 400 g for 10 min and the precipitate was washed with phosphate-
buffered saline (PBS). Flow cytometric analysis was performed with a FACSVantage 
flow cytometer (Becton Dickinson). The percentage viability was calculated in 
comparison with the control culture. The IC50 was calculated using linear regression 
analysis from the Kc values of the concentrations employed (0.1–100 µM). Epimastigote 
assays: The compounds were added in the same µM concentration than used before for 
Vero cells. The effects of each compound against epimastigote forms of T. cruzi were 
tested at 72 h using a Neubauer hemocytometric chamber. The antitrypanosomatid 
effect is expressed as the IC50, that is, the concentration required to give 50% growth 
inhibition, calculated by linear regression analysis from the Kc values of the 
concentrations employed. Amastigote assays: Vero cells were grown as described above 
in RPMI medium (Gibco). Cells were seeded at a density of 1 × 104 cells per well in 24-
well microplates (Nunc) with rounded coverslips on the bottom and cultured for 24 h. 
Afterwards, the cells were infected in vitro with metacyclic forms at a ratio of 10:1 over 
12 h. The nonphagocytosed parasites were removed by washing, and then the drugs (at 
	 8	
100, 50, 25, 10, 1, 0.5 0.25, and 0.1 µM) were added. Vero cells with the drugs were 
incubated for 72 h at 37°C in 5% CO2. The drug activity was determined on the basis of 
the number of amastigote forms in the treated and untreated cultures in methanol-fixed 
and Giemsa-stained preparations. The number of amastigote forms was determined by 
analyzing 200 host cells distributed in randomly chosen microscopic fields. The 
antitrypanosomatid effect is expressed as the IC50; Bz was included as reference drug. 
Trypomastigotes assay:  compounds were also evaluated in blood trypomastigote forms 
of T. cruzi. BALB/c female mice infected with T. cruzi were used 7 days after infection. 
Blood was obtained by cardiac puncture using 3.8% sodium citrate as an anticoagulant 
in a 7:3 blood:anticoagulant ratio. The parasitaemia in the infected mice was about 1 × 
105 parasites/mL. The compounds were diluted in phosphate-buffered saline solution 
(PBS) to give a final concentration 10, 25, and 50 µM for each compound. Aliquots (20 
µL) of each solution were mixed in culture trays (96 wells) with 55 µL of infected blood 
containing the parasites at a concentration of approximately 1 × 106 parasites/mL. 
Infected blood with PBS, at the same concentrations as the products, was used as 
control. The plates were shaken for 10 min at room temperature and kept at 4°C for 24 
h. Each solution was examined microscopically (Olympus CX41) for parasite counting 
using the Neubauer haemocytometric chamber (a dilution of 1:100 in PBS was 
necessary to get into the range of counting). The activity (percent of parasites reduction) 
was compared with that of the control. 
These studies were complemented by infectivity assays on Vero cells with the most active 
compounds, representing a reproduction of the lifecycle in vitro. Briefly, Vero cells were 
grown under the same conditions expressed over 2 days. Afterwards, the cells were 
infected in vitro with metacyclic forms of T. cruzi at a ratio of 10:1. The drugs (IC25 
concentrations) were added immediately after infection and were incubated for 12 h at 
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37°C in 5% CO2; Bz was included as reference drug. The non-phagocytosed parasites 
and the drugs were removed by washing, and then the infected cultures were grown for 10 
days in fresh medium. Fresh culture medium was added every 48 h. The drug activity was 
determined from the percentage of infected cells, the number of amastigote forms per 
infected cell, and the number of trypomastigote forms in the medium, in treated and 
untreated cultures, as well as in methanol-fixed and Giemsa-stained preparations. The 
percentage of infected cells and the mean number of amastigote forms per infected cell 
were determined by analyzing 200 host cells distributed in randomly chosen microscopic 
fields every 48 h. The number of trypomastigote forms in the medium was determined 
using a Neubauer hemocytometric chamber every 48 h. 
Biological activity: In vivo assays 
The in vivo trypanocidal activities of the compounds were studied using a murine model 
from acute to chronic phases of Chagas disease, according to our previously published 
procedures.11 Briefly, groups of six Balb/c female albino mice (6−8 weeks old, 25−30 g 
weight) maintained under a 12 h dark/light cycle (lights on at 07:30 h) at a temperature of 
22 ± 3°C and provided with water and standard chow ad libitum, were inoculated through 
the intraperitoneal route with 5 × 103 blood trypomastigote forms of T. cruzi obtained from 
previously infected mice blood. The animals were divided as follows: I positive control 
group (6 mice infected but not treated) and II study group (6 mice infected and treated 
with the compounds under study). The administration of the tested compounds was 
initiated on the seventh day of infestation once the infection was confirmed, and doses of 
15 mg/kg body weight per day were administered for 5 consecutive days (7−12 days pi) 
through the intraperitoneal route; Bz was included as reference drug. Peripheral blood 
was obtained from the mandibular vein of each mouse (5 µL samples) and diluted in 495 
µL of PBS solution at a 1:100 dilution. The circulating parasite numbers were quantified 
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with a Neubauer’s chamber for counting blood cells. This counting was performed every 3 
days over 40 days (acute phase). The number of bloodstream forms was expressed as 
parasites/mL. After day 60, the mice entered the chronic phase of the experiment where 
parasitemia continued decreasing its levels progressively, independently of the treatment. 
So, on day 120, the parasitemia was checked and found to be undetectable by fresh blood 
microscopic examination; then, the mice received four intraperitoneal doses of 200 
mg/kg·w of body mass cyclophosphamide monohydrate (CP) (ISOPAC®) on alternate 
days. The efficacy of such an immunosuppression procedure to assess cryptic infection 
was verified by the high parasitemias under microscopic examination and/or mortality 
close to the 100% of chronically untreated mice, having received the immunosuppression 
treatment. Within 1 week after the last CP injection, parasitemia was evaluated according 
to the procedure described for the acute phase to quantify the presence of blood 
trypomastigote forms as a reactivation rate. Finally, the mice were bled out under gaseous 
anaesthesia (CO2) through a heart puncture and the blood was collected. Blood was 
incubated for 2 h at 37ºC and then over night at 4ºC in order to allow clotting and to obtain 
the serum from the samples after centrifuging the supernatant twice at 1000 and 2700 g, 
consecutively. The serum was divided into aliquots and used for ELISA and biochemical 
analyses, as explained below. Hearts were harvested and immediately flushed free of blood 
by gentle infusion of 10 mL of prewarmed PBS through the left ventricle in order to avoid 
contamination of collected tissue with blood parasites. Afterwards, they were frozen at –
80ºC and stored until they were used for DNA extraction. 
Toxicity testing was also included to determinate the potential damage that the compounds 
could cause for the host, which was measured by analysing different biochemical 
parameters as markers of the kidney, heart and liver profiles. A fraction of the obtained 
serum was sent to the Biochemical Service at the University of Granada, where a series of 
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parameters were measured according to the commercial kits acquired from Cromakit® by 
BS-200 Chemistry Analyser ( Shenzhen mindray, Biomedical electronics co., Ltd.). With 
the levels obtained for different populations of sera (n = 15, n = 6), we calculated the mean 
value and standard deviation. Finally, we also calculated the confidence interval for the 
mean normal populations based on a confidence level of 95% [100 × (1–α) = 100 × 
(1.05)%]. The obtained ranges are shown in Table 2, which allows the comparison and 
analysis of the sera studied in this work. 
Mechanism of action 
In order to get an insight into the molecular mode of action of the compounds, a 1H NMR 
study was conducted, according to a previously published procedure,10 and the changes in 
the nature and quantity of the excreted metabolites were examined to gain information 
about the effect of the compounds on the energetic metabolism of parasites. Shortly, 
cultures of T. cruzi epimastigote forms (initial concentration of 5 x 105 cells/mL) received 
IC25 of the compounds (except for the control cultures). After incubation for 96 h at 28°C, 
the cells were centrifuged at 400 g for 10 min. The supernatants were collected in order to 
determine the excreted metabolites through 1H NMR, and the chemical shifts were 
expressed in parts per million (ppm), using dimethyl sulphoxide (DMSO) as the reference 
signal. One-dimensional 1H NMR spectra were acquired on VARIAN DIRECT DRIVE 
400 MHz Bruker spectrometer with AutoX probe using D2O. The assignments of 
metabolites were based on 1D NMR spectrum. The chemical shifts used to identify the 
respective metabolites were consistent with those described previously by our group10. In 
addition, the human metabolome database (http://www.hmdb.ca/) was also used for this 
purpose. The spectral region of 1.0 to 5.5 ppm was bucketed into a frequency window of 
0.1 ppm. The region corresponding to water (4.5 to 5.5 ppm) was excluded during binning 
to avoid artefacts due to pre-saturation of water, and the region corresponding to glucose 
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(3.4 to 3.8 ppm) was also excluded. The aromatic region was excluded because the signal 
to noise ratio in this region was poorer compared to that of the aliphatic region. The peak 
(2.6 ppm) corresponding to DMSO was removed before binning. The resulting integrals 
were normalised to the working region (1.0 to 3.4) ppm of the spectrum to correct for 
inter-sample differences in dilution. The binning and normalisations were achieved using 
Mestrenova 9.0 software. The matrix obtained in Mestrenova was imported to Microsoft 
Excel for further data analyses. 
In addition, ultra-structural alterations of the parasites treated with the compounds were 
investigated using transmission electron microscopy (TEM), briefly, epimastigote forms of 
T. cruzi were cultured at a density of 5 × 105 cells/mL in each corresponding medium 
containing the compounds tested at their IC25 concentrations. After 72 h, these cultures 
were centrifuged at 400 g for 10 min and the pellets produced were washed in PBS and 
then mixed with 2% (v/v) paraformaldehyde/glutaraldehyde in 0.05 M cacodylate buffer 
(pH 7.4) for 4 h at 4ºC. Following this, the pellets were prepared for TEM study using a 
previously described technique.11.  
The ability of the compounds to interfere with the antioxidant defence of the parasites was 
evaluated by studying them as putative inhibitors of Fe-SOD (in contrast to human Cu–Zn-
SOD). In order to do that, epimastigote forms of T. cruzi, cultured as described above, were 
collected by centrifugation. The pellet was suspended in 3 mL of STE buffer (0.25 M 
sucrose, 25 mM Tris–HCl, 1 M EDTA, pH 7.8) and the cells were disintegrated through 
three cycles of ultra sonication, each for 30 s at 60 W. The homogenate was centrifuged for 
5 min at 1500 g and 4ºC, and the pellet was washed three times in ice-cold STE buffer. 
This fraction was centrifuged (2500 g for 10 min at 4ºC) and the supernatant was collected. 
The protein concentrations in the supernatant were determined using the Bradford method. 
The Fe–SOD and CuZn–SOD activities were determined using the method described by 
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Beyer and Fridovich, which measures the reduction of nitrobluetetrazolium (NBT) by 
superoxide ions. Into each cuvette, 845 µL of the stock solution [3 mL of L-methionine 
(300 mg, 10 mL−l), 2 mL of NBT (1.41 mg, 10 mL−1) and 1.5 mL of Triton X-100 1% 
(v/v)] was added, together with 30 µL of the parasite homogenate fraction, 10 µL of 
riboflavin (0.44 mg, 10 mL−l) and an equivalent volume of the of the compound solution. 
Five different concentrations were used for each compound (1–100 µM). In the control 
experiment, the volume was made up to 1000 µL with 50 mM potassium phosphate buffer 
(pH 7.8), whereas 30 µL of the parasite homogenate fraction was added to mixtures 
containing the compounds. Then, the absorbance (A0) was measured at 560 nm in a 
spectrophotometer. Every cuvette was illuminated with a fixed lamp light for 10 min under 
constant stirring and the absorbance (A1) was measured. The human CuZn–SOD, 
coenzymes, and substrates used in these assays were purchased from Sigma Chemical Co. 
The obtained data were analysed using the Newman–Keuls test. 
Statistical analyses 
Data were recorded on an Excel spread sheet (Microsoft, Redmond, WA, USA), and 
statistical analysis performed by using SPSS Statistics (V. 17) software (IBM, NY, USA). 
The t test for paired samples was used to verify whether there were differences between the 
assays used, with p-0.05 considered statistically significant and with a 95% confidence 
interval. Also statistical studies based on contingency tables (prevalence) were conducted, 
together with the x2 test of the relationship between variables. 
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Results and discussion 
In vitro trypanosomicidal evaluation  
Five out of seven of the polyamines showed better selectivity indexes (SI = IC50 Vero 
cells/IC50 extracellular and intracellular forms of T. cruzi) compared to the reference drug 
Bz. As summarised in Table 1, compound 6, with SI values 13, 17 and 21 times higher 
than those of Bz, was the best compound, independent of the parasite stage (epimastigote, 
amastigote and trypomastigote forms, respectively). This activity meets good criteria to 
consider it as a strong candidate to undergo in vivo studies.  
To obtain more accurate information about the most active polyamine, 6, the development 
of the parasites in Vero cells was studied by measuring the rates of infection and the 
average number of amastigote and trypomastigote forms present during a ten-day treatment 
period. Vero cells were infected with metacyclic forms of T. cruzi and the gradual 
differentiation into amastigote forms was followed. During the observation time, in the 
control group, the rate of infection of the host cells gradually increased, reaching 99% 
invasion at the end of the experiment (Fig. 2A). The test was repeated in the presence of 
the reference drug and in the presence of compound 6, at their IC25 concentrations. It was 
found that the rate of infection decreased in all cases, with respect to the control, and 
compound 6 showed reductions in the infection rate of 81% thus with much a higher 
efficiency than Bz (19% reduction) (p-value = 0.031).  
In terms of the average number of amastigote forms per Vero cell (Fig. 2B), the results 
were consistent with those mentioned above for infection rates. After treatment, compound 
6 significantly reduced the number of amastigote forms per cell by 56%, whereas Bz 
showed reduction of only a 39%. The average number of amastigote forms increased to a 
maximum on the sixth day of culture, but decreased thereafter; the rupture of Vero cells 
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released trypomastigote forms. In terms of the number of trypomastigote forms found per 
millilitre of culture medium (Fig. 2C), a maximum was reached on day 10 (9.5 × 103 
trypomastigote forms/mL) for the control, whereas this value was substantially reduced by 
the reference drug (41%), but even more so by compounds 6 (88%). In summary, the 
results of the parasite spreading in Vero cells are in agreement with those of the 
trypanocidal activity reported in Table 1 for intracellular and extracellular forms of T. cruzi, 
with compound 6 being much better than any of the other drug candidates tested. 
In vivo activity of tetradentate polyamines  
The promising in vitro results prompted us to study the in vivo activity of this polyamine in 
female BALB/c mice. As the effectiveness of the drugs currently in use against Chagas 
disease varies widely between the acute and chronic phase, we decided to evaluate the 
impact of our compound on both phases. For the acute phase experiments, we considered 
the first 40 days after infection (dpi), whereas the effect on the chronic phase was studied 
between days 40 and 120 after infection. The intraperitoneal (i.p.) doping route was 
preferred over the intravenous procedure, because it is well known that i.p. treatment 
substantially reduces animal mortality.12 In fact, no mouse died in any of our experiments 
with either the control or with the compound assayed at the concentrations used (15 mg/kg 
of body mass). However, the survival percentage for the mice treated with Bz was only 
about 80%. The female mice were inoculated with trypomastigote forms, as described in 
the material and methods section, and i.p. treatment with the compounds was started five 
days post-infection and maintained for five alternated days. A group of mice (control 
group) was treated in the same manner, but using only the vehicle. During the study of 
acute-phase activity, the level of parasitaemia was determined every two days. Fig. 3 
shows the number of trypomastigote forms found during the acute phase (1–40 dpi). On 
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the day of maximum parasite burden (20–22 days after infection), the tested compound 
greatly reduced the number of blood trypomastigote forms compared with the control 
group. Furthermore, compounds 6, lowered the level of parasitaemia on day 40 by 61%, 
being this effect significantly greater than that found for the reference drug (11%). 
Statistical tests revealed the effect of the comp 6 in decreasing the parasitemia levels with a 
p-value = 0.0017 < α = 0.05.  
Therefore, this group of mice, treated with compound 6 where kept until 120 dpi (late 
chronic phase, in which there are no parasites remaining in the bloodstream that are 
quantifiable by fresh blood analysis) when the mice underwent an immunosuppression 
treatment as it was explained in the Material and Methods section. Fig. 4A shows the 
reactivation of parasitaemia after immunosuppression. It can be appreciated that the 
control group recovers half of its initial peak of parasitaemia, with a reactivation of 55 %. 
In contrast, the treated group show a parasitaemia load of 37.2% with respect to their 
burden peak when the mice have been administered with compound 6. To test this 
hypothesis χ² test we were performed using Fisher statistic (being a 2x2 table) to obtain a 
p- value of 0.021 < α = 0.05 . ELISA assays offer an alternative method for verifying the 
effectiveness of these three compounds in the chronic phase after being challenged with an 
immunosuppression cycle. Fig. 4B shows the total Ig-G levels of anti-T. cruzi and, 
according to previous reports, the titer of Ig-G in Balb/c becomes stable during chronic 
phase of the disease;13 this is confirmed in fig. 4B. The control group showed an almost 
doubling in the Ig-G levels in response to the presence of the parasite in the bloodstream 
after immunosuppression. However, in the treated group, the differences between 
immunosuppressed (IS) and non-immunosuppressed (non-IS) groups were smaller and not 
significant in the case of compound 6. According to the Fisher’s statistic, the equality 
between both treatments was rejected (p- values of 0.019 and 0.02). This means that the 
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parasite-specific Ig-G levels were not higher, just proportional, than the remaining amount 
of total unspecific Ig-G caused by the hypergammaglobulinaemia characteristic of the 
infection by Trypanosoma cruzi.14  
Finally, fig. 4C shows the polymerase chain reaction (PCR) results after necropsy. The 
hearts were grinded and underwent a total DNA extraction and amplification of a fragment 
within the parasite SOD gene; the hearts of the control animals showed the expected 
presence of the parasite, since the cardiac tissue is the main target tissue for this particular 
strain of T. cruzi. In contrast, the hearts from mice treated with compound 6 were relatively 
clean (2 hearts out of 6) from parasites, thus confirming the partial curative effect of these 
compounds at this dosage. Biochemical clinical parameters were tested in different groups 
of BALB/c mice infected with Trypanosoma cruzi in different experimental situations 
(Table 2), showing that an increase in the dosage does not cause a toxicity risk. All 
biochemical parameters tested, regarding the kidney, heart and liver profiles, were not 
altered after compound administration.  
In order to improve the effectiveness of compound 6, we must take into consideration an 
increase in the dosage for future experiments and modify the schedule of treatment for a 
better exposure of the compound in the bloodstream.  
Metabolite excretion study 
As trypanosomatids are unable to completely degrade glucose to CO2, they excrete a 
considerable portion of their hexose skeleton as partially oxidised fragments in the form of 
fermented metabolites, whose nature and percentage depend on the pathway used for 
glucose metabolism.15,16 The catabolism products in Trypanosoma cruzi were acetate and 
succinate, with smaller percentages of L-alanine and D-lactate, in agreement with the data 
in previously published reports.17 Detection of large amounts of succinate as a major end 
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product is an usual feature, because it relies on glycosomal redox balance, enabling re-
oxidation of the NADH produced in the glycolytic pathway. Succinic fermentation 
requires only half of the phosphoenolpyruvate produced to maintain the NAD+/NADH 
balance, and the remaining pyruvate is converted inside the mitochondria and the cytosol is 
converted into acetate, D-lactate, L-alanine or ethanol, according to the degradation 
pathway followed by each species.18 In order to obtain some information concerning the 
effect of the tested compounds on glucose metabolism in the parasites, we obtained 1H 
NMR spectra of T. cruzi epimastigote forms after treatment with compound 6, from which 
the final excretion products were identified qualitatively and quantitatively (spectra not 
shown). The results were compared with those obtained from parasites maintained in a 
cell-free medium (control) for four days after inoculation with the parasite. The 
characteristic presence of acetate, succinate, D-lactate and L-alanine was confirmed in the 
control experiments. As expected, succinate and acetate were the most abundant end 
products identified. However, after treatment of the parasites with compound 6, the 
excretion of metabolites was slightly altered at the dosages employed. Fig. 5 displays these 
modifications with respect to the control at the height of the spectral peaks, corresponding 
to the most representative final excretion products. Marked differences in the catabolic 
pathways appeared, which seemed to be connected with the trypanocidal activity 
mentioned above. The most remarkable differences were the decreased the amount of 
succinate by 17%; in addition, an increase in the amount of acetate, D-lactate and L-alanine 
by 17, 18 and 21%, respectively, was found upon treatment with compound 6. A 
nonparametric test in each case was performed and a p- value < α = 0.05 ( p -values 0.045 , 
0.087 , 0.0013 and 0.012 ) was obtained. So, in conclusion, even though the disturbances 
were quantifiable, we could not attribute the metabolism of the involved enzymes to the 
direct targets of the compounds. 
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Figure 2. Effect of compound 6, and Bz on the infectivity of T. cruzi in Vero cells. (A) Rate 
of infection, (B) mean number of amastigote forms per infected Vero cell and (C) number of 
trypomastigote forms in the culture medium after treatment with the IC25 of the control 
(filled circles), Bz (filled squares), compound 6 (filled triangles). The results are the mean 
	 21	
values of three separate experiments and the error bars represent the mean +/- standard 
deviation.  
 
Figure 3. Parasitemia in the murine model of acute Chagas disease. Control (filled squares) 
and doses of 15 mg/kg body mass of Bz (filled circles), compound 6 (filled triangles). The 
grey shading represents the days of treatment. Values are the means of six separate mice and 
error bars represent the mean +/- standard deviation.  
	 22	
C	
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Figure 4. Post-mortem analyses on the final day after necropsy. (A) Percentage of 
reactivation of blood parasitemia after immunosuppression, (B) total Ig-G levels of anti-T. 
cruzi, where the error bars represent the mean +/- standard deviation of three mice and (C) 
PCR of mouse heart tissue. M, marker; -, PCR negative control; +, PCR positive control; 
lanes 1–3 represent the non-IS mice in the final days of the experiment; lanes 4–6 represent 
the IS mice; A, infection control group; B, infected and treated with compound 6. 
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Figure 5. Variation percentages in the height of the peaks corresponding to metabolites 
excreted by T. cruzi epimastigote forms in the presence of comp 6 at its IC25 compared to a 
control sample. 
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T
able 1. In V
itro A
ctivity, Toxicity and Selectivity Index found for polyam
inic com
pounds com
plex on 
extracellular and intracellular form
s  of Trypanosom
a cruzi.  
R
esults are averages of four separate determ
inations. aIC
50  = the concentration required to give 50%
 inhibition, calculated by linear 
regression  analysis from
 the K
c values at concentrations em
ployed (1, 10, 25, 50 and 100 µM
). bTow
ards C
ell V
ero after 72 h of 
culture. cSelectivity index =IC
50  C
ell V
ero/IC
50   extracellularand intracellular form
 of parasite. In brackets: num
ber of tim
es that 
com
pound exceeds the reference drug SI (on extracellular and intracellular form
s  of T. cruzi). 
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0.8 
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0.6 
C
om
p 1  
40.7±2.1 
20.8±1.7 
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17.9±3.1 
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5.7±0.8 
71.6±6.3 
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